Anthropic wants Claude to do more than write emails and debug code. It wants the AI to help make medicine.
On October 27, 2026, the company detailed progress across collaborations with six organizations using Claude and its Claude Science workbench for drug development. It also disclosed its own in-house drug programs. Most of that work is still preclinical, which means nothing has reached a patient yet.
Who is in, and what they built
The partner roster mixes big pharma, venture capital and startups. It includes BigHat Biosciences, Bristol Myers Squibb (BMS), Divergence Labs, Enveda, Generate Biomedicines and The Column Group.
The projects span several stages of the drug pipeline. Most sit in early phases such as hit generation and lead optimization, along with regulatory documentation.
Generate Biomedicines reported that Claude helped it produce genetic instructions for a CAR-T therapy that were approximately 70% shorter. CAR-T treatments reprogram a patient’s own immune cells to attack disease. Shorter instructions can make that engineering job more manageable.
Divergence Labs used Claude to generate approximately 35,000 antibody designs aimed at food allergies.
BigHat Biosciences said its work with Anthropic’s technology delivered more than 10x tighter binding, plus notable stability improvements. Binding measures how firmly a drug grips its target. A tighter grip generally signals a more potent candidate.
Enveda pointed to the paperwork side of the business. The company reported an 89% time reduction in regulatory and documentation processes.
The Column Group, a life sciences investor, used Claude for operational support while standing up a new biotech called Pleiades.
Bristol Myers Squibb has been using Claude since May 2026 for clinical trial planning. That includes assessing the probability that trials will succeed.
Anthropic goes into the lab itself
Anthropic has launched its own preclinical programs through its 2026 acquisition of Mithril Medicine.
Mithril, founded by Cody Tranbarger, focuses on rare childhood muscular dystrophies. Anthropic said the lead program has shown early promising results.
Separately, Novo Nordisk announced a collaboration with Anthropic on September 16, 2026. The Danish drugmaker plans to use Claude models to strengthen its research and development workflows. The deal fits Novo Nordisk’s stated ambition of becoming a leader in AI-driven healthcare, and it builds on earlier deployments of Anthropic’s technology.
Anthropic’s recent IPO filing hints at ambitions in the life sciences sector. A portfolio of named pharma partners, plus its own drug programs, gives the company a concrete story to tell public market investors about revenue beyond chatbots and coding.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.